drugset / Trial / NCT00194649

Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

NCT00194649

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men. We want to see if Miglustat will inhibit sperm production in men and act as a reversible male contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of sperm production. We believe Miglustat may have some potential as a safe, reversible male contraceptive.

Timeline

Start
2005-06
Primary completion
2006-01
Completion
2006-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Miglustat Small molecule 100 mg Oral

Indications

No indication recorded.